Paul Kramm, MD
Pain Medicine · Baton Rouge, LANPI 1891877130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,065 and has fallen 87.0% since, to $139 in 2025.
Across 289 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$858
- Teva Pharmaceuticals USA, Inc.$559
- Virtus Pharmaceuticals LLC$507
- Lilly USA, LLC$474
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$408
- AbbVie$406
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,850100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 47 | $858 |
| Teva Pharmaceuticals USA, Inc. | 32 | $559 |
| Virtus Pharmaceuticals LLC | 31 | $507 |
| Lilly USA, LLC | 31 | $474 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $408 |
| AbbVie(2 entities) | 22 | $406 |
| Lundbeck LLC | 10 | $196 |
| Biodelivery Sciences International, Inc. | 11 | $190 |
| Novartis | 9 | $146 |
| Amgen | 7 | $133 |
| Biohaven Pharmaceuticals, Inc. | 5 | $129 |
| Sentynl Therapeutics, Inc. | 12 | $128 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $113 |
| Almatica Pharma LLC | 4 | $85 |
| Valinor Pharma, LLC | 4 | $83 |
| Forte Bio-pharma LLC | 3 | $62 |
| Zyla Life Sciences, Inc. | 3 | $52 |
| Scilex Pharmaceuticals Inc. | 3 | $49 |
| Kaleo, Inc. | 3 | $47 |
| Pfizer | 3 | $45 |
| MDD US Operations, LLC | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 2 | $25 |
| Assertio Therapeutics, Inc. | 2 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| Revance Therapeutics, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Medtronic | 1 | $14 |
| Shionogi Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$105
How this compares
$4,857 in reported general payments places this provider in the 55th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 63 | $82,638 |
| OxycontinOxycodone Hcl | 41 | $69,717 |
| Levorphanol Tartrate | 18 | $42,514 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 723 | $25,427 |
| Oxycodone Hcl | 793 | $20,441 |
| Fentanyl | 99 | $19,999 |
| UbrelvyUbrogepant | 16 | $17,879 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 373 | $15,708 |
| Morphine Sulfate ErMorphine Sulfate | 358 | $14,787 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,760 |
| MovantikNaloxegol Oxalate | 26 | $11,647 |
| Oxymorphone Hcl ErOxymorphone Hcl | 27 | $8,366 |
| Tramadol Hcl | 269 | $3,999 |
| Gabapentin | 256 | $3,600 |
| Methadone Hcl | 75 | $2,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $858 | $82,63863 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $507 | $42,51418 claims |
| AbbVieUbrelvy | $406 | $17,87916 claims |
| PfizerNurtec Odt | $45 | $13,76013 claims |
| Almatica Pharma LLCSertraline Hcl | $85 | $17414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 97 pain medicine providers in Louisiana.
Other pain medicine in Baton Rouge
- Jason GremillionBaton Rouge$19K
- Barrett JohnstonBaton Rouge$14K
- Samir PatelBaton Rouge$11K
- Samita DasBaton Rouge$10K
- Andrew BarkerBaton Rouge$9K
- Jake TrahanBaton Rouge$9K
- William GraugnardBaton Rouge$7K
- Jyoti PhamBaton Rouge$4K
- Thomas MyersMandeville$118K
- Alan KayeNew Orleans$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.